Nutrition Publication

NNIW84 - Next-Generation Nutritional Biomarkers to Guide Better Health Care

Editor(s): E. E. Baetge, A. Dhawan A. M. Prentice . 84

Biomarkers are the backbones of our daily medical decision making. They indicatethe malfunction of organ systems and efficacy of therapeutic interventions.However, only in a few areas related to human nutrition and metabolism, biomarkersplay important roles to predict health and functional outcome, and areroutinely used in clinical practice. Parameters indicating the lipid status/metabolismwhich predict long-term cardiovascular risk and efficacy of targetedinterventions have been included in routine patient management for a longtime.Biomarkers of lipid status have also shown the limitations of our presentnutritional intervention strategies. Iron deficiency and overload can be preciselydiagnosed and managed by biomarkers, and it has recently been shown thatthe best ‘biomarker’ to guide treatment may be the physiological ‘determinant’of iron utilization (hepcidin). Interestingly, out of the ‘big four’ global nutritionaldeficiencies (vitamin A, zinc, iodine, and iron) which are associated withsignificant morbidity and mortality in humans, three still cannot be preciselydiagnosed by employing (biochemical) biomarkers. Therefore, interventionstrategies are mostly still targeted at population level and biomarkers play a limitedrole in research and decision making. Satisfactory pediatric nutritional biomarkersof outcome must be predictive of later functional health and ideallyremain stable over the period from infancy to childhood and adult life. Currenttraditional biomarkers such as anthropometry and blood pressure are indicesthat best fulfill those criteria. They are important to monitor long-term healthof children who were born with low birth weight in terms of malnutrition orobesity.New biomarkers which have recently been developed by employing highthroughputmetabolomic, proteomic, and genomic technologies indicate thatinpiduals are genetically and biochemically distinct. Our epigenome and metabolomecan be influenced by dietary, lifestyle, and environmental factors,which contribute to the heterogeneity observed in humans. Therefore, the riskfactors determined for populations cannot be applied to the inpidual, one hasForeword XIto accept ‘inpidual variability’. New biomarkers which indicate the inpidualrisk or benefit must not neglect the complexity of foods, lifestyle, and metabolicprocesses that contribute to health or disease and are significant challenges forpersonalizing dietary advice for healthy or diseased inpiduals. The 84th Nestlé Nutrition Institute (NNI) Workshop focused on values andlimitations of traditional nutritional biomarkers and opportunities of new biomarkers.NNI would like to thank the three Chairmen, Prof. Emmanuel E.Baetge (Switzerland), Prof. Anil Dhawan (UK), and Prof. Andrew Prentice,(UK) for their challenging and interesting program together and all speakers fortheir significant contributions. We would also thank the Nestlé Health ScienceInstitute and the Nestlé Research Centre for cooperation and support.

Related Articles

Systems-Level Nutrition Approaches to Define Phenotypes Resulting from Complex Gene-Environment Interactions

Author(s): J. Kaput

High-throughput metabolomic, proteomic, and genomic technologies have delivered21st-century data showing that humans cannot be randomized into groups: individualsare genetically and biochemically distinct. Gene-environment interactions caused byunique dietary and lifestyle factors contribute to the heterogeneity in physiologies observedin human studies.The risk factors determined for populations (i.e. the populationattributablerisk) cannot be applied to the individual. Developing individual risk/benefitfactors in light of the genetic diversity of human populations, the complexity of foods,culture and lifestyle, and the variety in metabolic processes that lead to health or diseaseare significant challenges for personalizing dietary advice for healthy or diseased individuals.

Applications of Nutritional Biomarkers in Global Health Settings

Author(s): A. M. Prentice

In global health settings, there are three generic areas that require reliable biomarkers ofnutritional status and function. Population surveillance needs to identify key nutrientdeficiencies (or excesses) to monitor progress towards elimination of nutritional imbalancesand to stratify populations into groups especially ‘at risk’ to whom public healthresources can be focused. Clinical interventions need biomarkers to help identify diseasepathways, to assist in targeting nutrient prescriptions, and to avoid potential harm ( the case of iron). Discovery science requires biomarkers in many domains, but especiallyin the study of nutrient-gene interactions and regarding the effects of nutritionalstatus on the epigenome.Each of these applications imposes different constraints on themethodology though in all cases the optimum biomarker would have high sensitivity andspecificity, would capture variation of functional significance, and would be cheap andeasy to apply. These attributes are hard to achieve, and recent progress towards nextgenerationbiomarkers, though holding much promise, has not yet delivered significantbreakthroughs in the global health setting. Recent efforts to overcome these problemsby two initiatives (BOND and INSPIRE) are highlighted as exemplars of a route map toprogress.

Next-Generation Biomarkers of Health

Author(s): B. van Ommen, S. Wopereis

Current biomarkers used in health care and in nutrition and health research are based onquantifying disease onset and its progress. Yet, both health care and nutrition should focuson maintaining optimal health, where the related biology is essentially differing frombiomedical science. Health is characterized by the ability to continuously adapt in varyingcircumstances where multiple mechanisms of systems flexibility are involved.A new generationof biomarkers is needed that quantifies all aspects of systems flexibility, openingthe door to real lifestyle-related health optimization, self-empowerment, and relatedproducts and services.

Bioinformatics: Novel Insights from Genomic Information

Author(s): R. E. W. Hancock

While scientific methods have dominated research approaches in biology over the pastdecades, it is increasingly recognized that the complexity of biological systems must beaddressed by a different approach, namely unbiased research involving the collection oflarge amounts of genome-wide information. To enable analysis of this information we andothers are developing a variety of computational tools that allow bioinformaticists andwet laboratory biologists to extract novel patterns of data from these results and generatenovel biological insights while generating new hypotheses for testing in the laboratory.There are two types of critical tools, databases to collate all information on biomolecules,especially interactions, and tools that reorganize information in a supervised (e.g. pathwayanalysis or gene ontology) or unsupervised (nonhierarchical clustering and network analysis)manner. Here we describe some of the tools we have developed and how we haveused these to gain new ideas in the general area of infection and innate immunity/inflammation.In particular, it is illustrated how such analyses enable novel hypotheses aboutmechanisms associated with diseases and the mechanisms of action of immunomodulatoryand other interventions, the definition of mechanism-based biomarkers/diagnostics,and prospective new interventions based on drug repurposing.

Biomarkers in Pediatric Liver Disease

Author(s): E. Kyrana, E. Fitzpatrick, A. Dhawan

The chronic nature of liver diseases in children and adults merits close follow-up for diseaseprogression and/or treatment evaluation. Disease progression involves injury to livercells resulting in cell death, varying degrees of inflammation, steatosis depending onthe insult, oxidative stress, and eventually fibrosis and cirrhosis unless the process is modifiedwith treatment or spontaneous recovery. Inflammation, cell death, and fibrosis arethe three major processes that determine the outcome of liver disease irrespective of theetiology.Markers to measure the activity or status of these parameters in a dynamic way,particularly via noninvasive methods, are urgently required. In this chapter, we summarizerecent advances in the identification of biomarkers of liver diseases: biomarkers correspondingto inflammation, cell death, fibrosis, and the development of malignancy.

Next-Generation Biomarkers for Iron Status

Author(s): H. Drakesmith

Iron is needed for oxygen transport, muscle activity, mitochondrial function, DNA synthesis,and sensing of hypoxia. The hierarchical master determinant of dietary iron absorptionand iron distribution within the body is the peptide hormone hepcidin. Hepcidin itself isregulated by a combination of signals derived from iron stores, inflammation, and erythropoieticexpansion. Iron deficiency and iron deficiency anemia are common and importantconditions that can be treated with iron preparations. However, other factors besidesiron deficiency can cause anemia, especially inflammation, which responds poorly to irontreatment, and inherited disorders of red blood cells, which are associated with accumulationof excess pathogenic iron.Assessment of iron status is challenging, and indices suchas serum ferritin, soluble transferrin receptor, and zinc protoporphyrin have specific weaknesses.Moreover, a diagnosis of iron deficiency or iron deficiency anemia is most usefulif the diagnosis also leads to effective treatment. Low levels of hepcidin allow iron absorptionand effective iron incorporation into red blood cells. The best ‘biomarker’ to guidetreatment may therefore be the physiological ‘determinant’ of iron utilization. Iron is alsoimportant in transplantation medicine and influences clinical outcome of arterial pulmonaryhypertension; here too, biomarkers including hepcidin may be useful to actively andbeneficially manage iron status.

The Search for Biomarkers of Long-Term Outcome after Preterm Birth

Author(s): J. R. C. Parkinson, M. J. Hyde, N. Modi

Preterm birth and survival rates are rising globally, and consequently there is a growingnecessity to safeguard life-long health. Epidemiological and other studies from aroundthe world point to a higher risk of adverse adult health outcomes following preterm birth.These reports encompass morbidities in multiple domains, poorer reproductive health,and reduced longevity. The contributions of genetic inheritance, intrauterine exposures,and postnatal care practices to this altered adult phenotype are not known. Early detectionis essential to implement preventive measures and to test protective antenatal andneonatal interventions to attenuate aberrant health trajectories.A satisfactory biomarkerof outcome must be predictive of later functional health and ideally remain stable overthe period from infancy to childhood and adult life. To date, blood pressure is the indexthat best fulfils these criteria. High throughput ‘omic’ technologies may identify biomarkersof later outcome and health risk. However, their potential can only be realized withinitial investment in large, longitudinal cohort studies, which couple serial metabolomicprofiling with functional health assessments across the life course.

Beyond Cholesterol - New Cardiovascular Biomarkers

Author(s): H. Mangge

Atherosclerosis (AS) is the primary pathological result of obesity. Vulnerable AS plaques causefatal clinical end points such as myocardial infarction and stroke. To prevent this, improvementsin early diagnosis and treatment are essential. Because vulnerable AS plaques are frequentlynonstenotic, they are preclinically undetectable using conventional imaging. Levelsof blood lipids, C-reactive protein, and interleukin-6 are increased, but are insufficient to indicatethe process of critical perpetuation before the end points present.More specific biomarkers(e.g. troponin, copetin, natriuretic peptides, growth differentiation factor-15, or solubleST2) indicate the acute coronary syndrome or cardiac insufficiency, but not a critical destabilizationof AS lesions in coronary or carotid arteries. Thus, valuable time (months to years) thatcould be used to treat the patient is wasted. An improved management of this dilemma mayinvolve better detection of variations in degrees of immune inflammation in plaques by usingnew biomarkers in blood and/or within the lesion (molecular imaging). Macrophage and T-cellpolarization, and innate and adaptive immune responses (e.g. Toll-like receptors) are involvedin this critical process. New biomarkers in these mechanisms include pentraxin 3, calprotectinsS100A8/S100A9, myeloperoxidase, adiponectin, interleukins, and chemokines.These proteinsmay also be candidates for molecular imaging using nuclear (magnetic resonance) imagingtools. Nevertheless, the main challenge remains: which asymptomatic individual shouldbe screened? At which time interval? Intense interdisciplinary research in laboratory medicine(biomarkers), nanomedicine (nanoparticle development), and radiology (molecular imaging)will hopefully address these questions.

Stratified Medicine: Maximizing Clinical Benefit by Biomarker-Driven Health Care

Author(s): S. Singh

Stratified medicine involves the use of biomarkers to differentiate patient populations intosubsets that provide more detailed information about the specific causes of conditions,and predict how patients will respond to a given drug or combination of drugs. Biomarker-driven patient stratification can empower clinicians by providing accurate assessmentsof patient status (diagnostic and prognostic utility) in order to strategize treatment planningand delivery (predictive and monitoring utility) based on information extracted frombiomarker profiles. This approach may also help presymptomatic individuals by delayingthe onset of disease, minimize the severity of the disease, or possibly prevent disease occurrence.Patients and clinicians may benefit from this approach as it may allow for thetransformation of current empirical ‘medical practice’ to efficient data-driven ‘individualizedtherapeutic strategies’ with a low risk of medical error. The health care industry mayalso benefit from this approach by designing clinical trials based on appropriate patientstratification. Here, recent advances in the field of stratified medicine are highlighted inthe context of our efforts to integrate this rapidly evolving concept into our research, andto ultimately develop potential diagnostic/prognostic/predictive products and nutritionalsolutions for individual patients and consumers.

The Gut Microbiome, Its Metabolome, and Their Relationship to Health and Disease

Author(s): G. D. Wu

Despite its importance in maintaining the health of the host, growing evidence suggeststhat gut microbiota may also be an important factor in the pathogenesis of various diseases.The composition of the microbiota can be influenced by many factors, includingage, genetics, host environment, and diet. There are epidemiologic data associating dietwith the development of inflammatory bowel disease as well as evidence that diet caninfluence both the form and the function of the microbiome. Based on this evidence, studiesare now underway to examine the effect of defined formula diets, an effective therapeuticmodality in Crohn’s disease, on both the gut microbiome and its metabolome as atherapeutic probe.Diet has an impact upon both the composition and the function of themicrobiota in part through small-molecule production that may influence the developmentof both immune-mediated and metabolic diseases. By comparing dietary intake, thegut microbiota, and the plasma metabolome in omnivores versus vegans, we provideevidence that the production of certain bacterial metabolites is constrained by the compositionof the gut microbiota. In total, these results demonstrate the potential promiseof dietary manipulation of the gut microbiota and its metabolome as a modality to bothmaintain health and treat disease.

The Scientific Challenge of Expanding the Frontiers of Nutrition

Author(s): S. Rezzi, S. Solari, N. Bouche, E. E. Baetge

Nutritional research is entering a paradigm shift which necessitates the modeling of complexinteractions between diet, genetics, lifestyle, and environmental factors. This requiresthe development of analytical and processing capabilities for multiple data and informationsources to be able to improve targeted and personalized nutritional approaches forthe maintenance of health. Ideally, such knowledge will be employed to underpin thedevelopment of concepts that combine consumer and medical nutrition with diagnostictargeting for early intervention designed to maintain proper metabolic homeostasis anddelay the onset of chronic diseases.Nutritional status is fundamental to any descriptionof health, and when combined with other data on lifestyle, environment, and genetics, itcan be used to drive stratified or even personalized nutritional strategies for health maintenanceand preventive medicine. In this work, we will discuss the importance of developingnew nutrient assessment methods and diagnostic capabilities for nutritional status togenerate scientific hypotheses and actionable concepts from which to develop targetedand eventually personalized nutritional solutions for health protection. We describe effortsto develop algorithms for dietary nutrient intake and a holistic nutritional profilingplatform as the basis of understanding the complex nutrition and health interactome.